“APOL1 Mediated Kidney Disease: What Does the Future Hold?” Seminar

We're headed to the National Kidney Foundation Clinicals in Austin, Texas where Michelle McNulty, MS will be speaking alongside Drs. Rasheed Gbadegesin and Jeffrey Kopp about "APOL1 Mediated Kidney Disease: What Does the Future Hold"? The session is happening over lunch on April 13 at 12 pm in Ballroom A, Austin Convention Center.

Can't make it in person? Tune into the #NKFClinicals livestream.

About the session:

APOL1-mediated kidney disease (AMKD) is a kidney disorder caused by certain apolipoprotein L1 (APOL1) genetic mutations. This genetic disease can lead to renal cell injury and damage to the glomeruli, resulting in proteinuria and progression to end stage kidney disease. This program will address APOL1 epidemiology and potential mechanisms of AMKD, as well as implications of genetic ancestry and approaches to testing, followed by a discussion of current and emerging therapies for AMKD.